Daiichi Sankyo US

Daiichi Sankyo US, established in 2003, functions as the dedicated U.S. subsidiary of the globally recognized pharmaceutical innovator, Daiichi Sankyo, Inc. This strategic positioning allows the company to leverage a rich heritage characterized by innovation, unwavering integrity, and profound accountability in its operations. Operating within the critical sectors of Pharmaceuticals and Healthcare, Daiichi Sankyo US generated a substantial revenue of $607.6M. The company maintains a significant operational footprint, managing its activities across 2 distinct locations to serve its target markets effectively.

With an employee base ranging from 1,000 to 5,000 professionals, Daiichi Sankyo US is deeply invested in the research, development, and delivery of novel therapeutic solutions. A core focus of its scientific endeavors lies in advancing oncology treatments, aiming to combat complex diseases. The company's commitment extends to patient support through comprehensive assistance programs, including vital prescription assistance services designed to enhance access to essential medicines. To gain insight into the individuals driving these initiatives, one can Meet Daiichi Sankyo US's team and explore their collective expertise and dedication.

Daiichi Sankyo US is committed to the entire lifecycle of pharmaceutical innovation, from initial discovery and rigorous development to the commercialization of groundbreaking medical products, with a pronounced emphasis on novel oncology agents. The company navigates a competitive landscape, contending with key players such as Aventis Pasteur, Synovia Pharma, and Allergan. Its overarching mission is to significantly improve patient outcomes and quality of life through the application of advanced medical science and the continuous expansion of its therapeutic pipeline. For comprehensive information,View more...